Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Hum Exp Toxicol ; 37(4): 350-357, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28441892

RESUMO

The aim of this study was to assess changes in bone mineral density (BMD) and cadmium (Cd) levels in blood and urine in individuals living in a Cd-contaminated area according to the type of osteoporosis medication over a three-year period. This follow-up study included 204 residents living in the vicinity of a closed copper refinery, who had been found to have elevated urinary or blood Cd levels. Cd levels in the blood and urine, as well as BMD, were measured every 6 months. After the first BMD measurement, individuals were prescribed antiresorptives such as alendronate or vitamin D and calcium, according to their BMD. Subjects were classified according to the type of medicine provided over the previous 6 months. General linear models controlling for other factors were used to evaluate the effects of each type of medication on the participants' Cd levels and BMD. Spinal BMD showed a significant increase in the antiresorptive group compared to the nontreatment group. Significant decreases in blood Cd levels were found in the vitamin D and calcium group, in comparison to the nontreatment group, as well as a marginally significant decrease in the antiresorptive group. The vitamin D and calcium group showed a significantly greater decrease in urinary Cd levels than the nontreatment group. In contrast, antiresorptive medication was found to have a negative effect on urinary Cd excretion. These results suggest that vitamin D and calcium treatment for osteoporosis lowers blood Cd levels more effectively and improves urinary Cd excretion.


Assuntos
Alendronato/uso terapêutico , Conservadores da Densidade Óssea/uso terapêutico , Densidade Óssea/efeitos dos fármacos , Cádmio/sangue , Cádmio/urina , Cálcio/uso terapêutico , Suplementos Nutricionais , Poluentes Ambientais/sangue , Poluentes Ambientais/urina , Osteoporose/tratamento farmacológico , Vitamina D/uso terapêutico , Absorciometria de Fóton , Idoso , Carga Corporal (Radioterapia) , Cobre , Feminino , Humanos , Masculino , Metalurgia , Pessoa de Meia-Idade , Osteoporose/diagnóstico , Osteoporose/fisiopatologia , Eliminação Renal , República da Coreia , Fatores de Tempo , Resultado do Tratamento
2.
J Biochem ; 118(5): 989-95, 1995 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8749317

RESUMO

The structure of the echinomycin complex with the self-complementary DNA decamer d(ACGTTAACGT)2 has been investigated in solution by proton NMR spectroscopy. Echinomycin binds as a bisintercalator at the CpG steps. An analysis of the intermolecular NOE patterns defined the position and orientation of the bound drug molecule. The terminal A.T base pairs are Hoogsteen base-paired, whereas the central four A.T base pairs are clearly Watson-Crick base-paired. Thus, the presence of the extra A.T base pairs between the binding sites appears to prevent the formation of Hoogsteen base pairs immediately adjacent to the binding site. All four central A.T base pairs are destabilized relative to those in the free DNA. Because there is no evidence for unwinding of the DNA duplex in the complex relative to the free DNA, we conclude that the hypersensitivity to DNA cleavage reagents distal to echinomycin binding sites might be due to the destabilization of DNA structure induced by the drug binding.


Assuntos
Adenina/química , Proteínas de Ligação a DNA/química , Equinomicina/química , Espectroscopia de Ressonância Magnética , Oligonucleotídeos/química , Timina/química , Composição de Bases , Sequência de Bases , Sítios de Ligação , Dados de Sequência Molecular , Estrutura Molecular , TATA Box
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA